Compare BHF & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHF | ABCL |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.5B |
| IPO Year | 2018 | 2020 |
| Metric | BHF | ABCL |
|---|---|---|
| Price | $52.27 | $11.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $57.71 | $8.40 |
| AVG Volume (30 Days) | 949.9K | ★ 8.7M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.06 | 10.91 |
| EPS | ★ 2.84 | N/A |
| Revenue | ★ $6,766,000,000.00 | $75,128,000.00 |
| Revenue This Year | $27.10 | N/A |
| Revenue Next Year | $1.09 | $21.85 |
| P/E Ratio | $18.74 | ★ N/A |
| Revenue Growth | 43.23 | ★ 160.56 |
| 52 Week Low | $43.25 | $2.75 |
| 52 Week High | $66.80 | $12.15 |
| Indicator | BHF | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 17.63 | 73.83 |
| Support Level | N/A | $3.38 |
| Resistance Level | $64.01 | N/A |
| Average True Range (ATR) | 1.72 | 0.87 |
| MACD | -0.86 | 0.35 |
| Stochastic Oscillator | 3.86 | 87.21 |
Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are: Annuities, that derives majority of the revenue, includes variable, fixed, index-linked, and income annuities; The life segment includes variable, term, universal, and whole life policies; The Run-off segment consists of products that are no longer actively sold and are separately managed, including ULSG, structured settlements, pension risk transfer contracts, certain company-owned life insurance policies and certain funding agreements; and The Corporate & Other segment consists of activities related to funding agreements associated with the company.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.